Literature DB >> 10330353

Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21.

W Balemans1, J Van Den Ende, A Freire Paes-Alves, F G Dikkers, P J Willems, F Vanhoenacker, N de Almeida-Melo, C F Alves, C A Stratakis, S C Hill, W Van Hul.   

Abstract

Sclerosteosis is an uncommon, autosomal recessive, progressive, sclerosing, bone dysplasia characterized by generalized osteosclerosis and hyperostosis of the skeleton, affecting mainly the skull and mandible. In most patients this causes facial paralysis and hearing loss. Other features are gigantism and hand abnormalities. In the present study, linkage analysis in two consanguineous families with sclerosteosis resulted in the assignment of the sclerosteosis gene to chromosome 17q12-q21. This region was analyzed because of the recent assignment to this chromosomal region of the gene causing van Buchem disease, a rare autosomal recessive condition with a hyperostosis similar to sclerosteosis. Because of the clinical similarities between sclerosteosis and van Buchem disease, it has previously been suggested that both conditions might be caused by mutations in the same gene. Our study now provides genetic evidence for this hypothesis.

Entities:  

Mesh:

Year:  1999        PMID: 10330353      PMCID: PMC1377909          DOI: 10.1086/302416

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  32 in total

1.  Sclerosteosis. A case report.

Authors:  Y Sugiura; T Yasuhara
Journal:  J Bone Joint Surg Am       Date:  1975-03       Impact factor: 5.284

2.  Hyperostosis corticalis generalisata congenita.

Authors:  H M Worth; D G Wollin
Journal:  J Can Assoc Radiol       Date:  1966-06

3.  [Dominant generalized cortical hyperostosis with multiple involvement of the cranial nerves].

Authors:  J Lapresle; P Maroteaux; R Kuffer; G Said; O Meyer
Journal:  Nouv Presse Med       Date:  1976-11-27

4.  [New cases of familial generalized cortical hyperostosis with dominant transmission (Worth's type) (author's transl)].

Authors:  M Vayssairat; A Prier; C Meisel; J P Camus; J Grellet
Journal:  J Radiol Electrol Med Nucl       Date:  1976-10

5.  The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals.

Authors:  P Beighton; L Durr; H Hamersma
Journal:  Ann Intern Med       Date:  1976-04       Impact factor: 25.391

6.  Sclerosteosis: report of a case in a black African man.

Authors:  P Tacconi; P Ferrigno; L Cocco; A Cannas; G Tamburini; P Bergonzi; M Giagheddu
Journal:  Clin Genet       Date:  1998-06       Impact factor: 4.438

7.  Autosomal dominant osteosclerosis.

Authors:  M I Gelman
Journal:  Radiology       Date:  1977-11       Impact factor: 11.105

8.  Autosomal dominant osteosclerosis.

Authors:  R J Gorlin; L Glass
Journal:  Radiology       Date:  1977-11       Impact factor: 11.105

9.  Van Buchem's disease (hyperostosis corticalis generalisata)

Authors:  R H Owen
Journal:  Br J Radiol       Date:  1976-02       Impact factor: 3.039

10.  Van Buchem's disease (hyperostosis corticalis generalisata familiaris). A case report.

Authors:  D P Dyson
Journal:  Br J Oral Surg       Date:  1972-03
View more
  36 in total

Review 1.  A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.

Authors:  Kevin A Maupin; Casey J Droscha; Bart O Williams
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts.

Authors:  Damian C Genetos; Chrisoula A Toupadakis; Leah F Raheja; Alice Wong; Savvas E Papanicolaou; David P Fyhrie; Gabriela G Loots; Clare E Yellowley
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

3.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Authors:  Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

Review 4.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

5.  Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13.

Authors:  K Janssens; R Gershoni-Baruch; E Van Hul; R Brik; N Guañabens; N Migone; L A Verbruggen; S H Ralston; M Bonduelle; L Van Maldergem; F Vanhoenacker; W Van Hul
Journal:  J Med Genet       Date:  2000-04       Impact factor: 6.318

Review 6.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

7.  Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.

Authors:  Su Jin Kim; Tadeusz Bieganski; Young Bae Sohn; Kazimierz Kozlowski; Mikhail Semënov; Nobuhiko Okamoto; Chi Hwa Kim; Ah-Ra Ko; Geung Hwan Ahn; Yoon-La Choi; Sung Won Park; Chang-Seok Ki; Ok-Hwa Kim; Gen Nishimura; Sheila Unger; Andrea Superti-Furga; Dong-Kyu Jin
Journal:  Hum Genet       Date:  2011-01-09       Impact factor: 4.132

Review 8.  Sclerostin: from bench to bedside.

Authors:  Sakae Tanaka; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2020-11-18       Impact factor: 2.626

9.  Signaling by bone morphogenetic proteins directs formation of an ectodermal signaling center that regulates craniofacial development.

Authors:  Silvia Foppiano; Diane Hu; Ralph S Marcucio
Journal:  Dev Biol       Date:  2007-09-20       Impact factor: 3.582

10.  Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.

Authors:  Hong Y Choi; Marco Dieckmann; Joachim Herz; Andreas Niemeier
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.